Clinical trial
A Phase II Study of ARQ 501 in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
NCT00102700 is registered in ClinicalTrials.gov with ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of ARQ 501 in Combination With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma
- Lead sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- January 31, 2005
- Completion date
- January 31, 2007
- Enrollment
- 66
- Sites
- 15
Conditions
As the registry lists them; a condition with its own page is linked.
adenocarcinoma, pancreatic cancer